SCHEDULE 13G 0001747888 XXXXXXXX LIVE Common stock, $.01 par value per share 02/24/2026 0000313143 Haemonetics Corporation 405024100 125 SUMMER STREET BOSTON MA 02110 Rule 13d-1(c) North Peak Capital Management, LLC DE 0.00 1882037.00 488458.00 1882037.00 2370495.00 N 5.1 IA OO The figures in Items 6, 8, and 9 include (1) 135,354 shares of Common stock, $.01 par value per share ("Common Stock") of Haemonetics Corporation (the "Issuer") held directly by North Peak Capital Partners, LP, (2) 993,566 shares of Common Stock held directly by North Peak Capital Partners II, LP, (3) 651,061 shares of Common Stock held directly by North Peak Capital Alpha Fund, LP and (4) 102,056 shares of Common Stock held directly by North Peak Capital Ultra Fund, LP. The figure in Item 11 is based upon 46,471,350 Common Stock of the Issuer outstanding as of January 30, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the reporting period ended December 27, 2025 filed with the U.S. Securities and Exchange Commission (the "Commission") on February 5, 2026. North Peak Capital GP, LLC DE 0.00 1882037.00 0.00 1882037.00 1882037.00 N 4.0 OO The figures in Items 6, 8, and 9 include (1) 135,354 shares of Common Stock of the Issuer held directly by North Peak Capital Partners, LP, (2) 993,566 shares of Common Stock held directly by North Peak Capital Partners II, LP, (3) 651,061 shares of Common Stock held directly by North Peak Capital Alpha Fund, LP and (4) 102,056 shares of Common Stock held directly by North Peak Capital Ultra Fund, LP. The figure in Item 11 is based upon 46,471,350 Common Stock of the Issuer outstanding as of January 30, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the reporting period ended December 27, 2025, filed with the Commission on February 5, 2026. North Peak Capital Partners, LP DE 0.00 135354.00 0.00 135354.00 135354.00 N 0.3 PN The figure in Item 11 is based upon 46,471,350 Common Stock of the Issuer outstanding as of January 30, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the reporting period ended December 27, 2025, filed with the Commission on February 5, 2026. North Peak Capital Partners II, LP DE 0.00 993566.00 0.00 993566.00 993566.00 N 2.1 PN The figure in Item 11 is based upon 46,471,350 Common Stock of the Issuer outstanding as of January 30, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the reporting period ended December 27, 2025, filed with the Commission on February 5, 2026. North Peak Capital Alpha Fund, LP DE 0.00 651061.00 0.00 651061.00 651061.00 N 1.4 PN The figure in Item 11 is based upon 46,471,350 Common Stock of the Issuer outstanding as of January 30, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the reporting period ended December 27, 2025, filed with the Commission on February 5, 2026. North Peak Capital Ultra Fund, LP DE 0.00 102056.00 0.00 102056.00 102056.00 N 0.2 PN The figure in Item 11 is based upon 46,471,350 Common Stock of the Issuer outstanding as of January 30, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the reporting period ended December 27, 2025, filed with the Commission on February 5, 2026. Michael Kevin Kahan X1 0.00 1882037.00 0.00 1882037.00 1882037.00 N 4.0 HC IN The figures in Items 6, 8, and 9 include (1) 135,354 shares of Common Stock of the Issuer held directly by North Peak Capital Partners, LP, (2) 993,566 shares of Common Stock held directly by North Peak Capital Partners II, LP, (3) 651,061 shares of Common Stock held directly by North Peak Capital Alpha Fund, LP and (4) 102,056 shares of Common Stock held directly by North Peak Capital Ultra Fund, LP. The figure in Item 11 is based upon 46,471,350 Common Stock of the Issuer outstanding as of January 30, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the reporting period ended December 27, 2025, filed with the Commission on February 5, 2026. Jeremy Steven Kahan X1 0.00 1882037.00 0.00 1882037.00 1882037.00 N 4.0 HC CO The figures in Items 6, 8, and 9 include (1) 135,354 shares of Common Stock of the Issuer held directly by North Peak Capital Partners, LP, (2) 993,566 shares of Common Stock held directly by North Peak Capital Partners II, LP, (3) 651,061 shares of Common Stock held directly by North Peak Capital Alpha Fund, LP and (4) 102,056 shares of Common Stock held directly by North Peak Capital Ultra Fund, LP. The figure in Item 11 is based upon 46,471,350 Common Stock of the Issuer outstanding as of January 30, 2026, as disclosed in the Issuer's quarterly report on Form 10-Q for the reporting period ended December 27, 2025, filed with the Commission on February 5, 2026. Haemonetics Corporation 125 SUMMER STREET, BOSTON, MA, 02110 This statement is jointly filed by and on behalf of each of North Peak Capital Management, LLC, a Delaware limited liability company ("North Peak Management"), North Peak Capital GP, LLC, a Delaware limited liability company ("North Peak GP"), North Peak Capital Partners, LP, a Delaware limited partnership ("Fund I"), North Peak Capital Partners II, LP, a Delaware limited partnership ("Fund II"), North Peak Capital Alpha Fund, LP, a Delaware limited partnership ("Alpha Fund"), North Peak Capital Ultra Fund, LP, a Delaware limited partnership ("Ultra Fund"), Jeremy S. Kahan and Michael K. Kahan (each, a "Reporting Person" and collectively, the "Reporting Persons"). North Peak Management is the investment manager of, and may be deemed to indirectly beneficially own securities owned by, each of Fund I, Fund II, Alpha Fund and Ultra Fund. North Peak Management is also an investment adviser to a separately managed account of an advisory client and may be deemed to beneficially own securities directly in such separately managed account, but North Peak Management does not have any voting authority with respect to any securities in such separately managed account. North Peak GP is the general partner of, and may be deemed to indirectly beneficially own securities owned by, each of Fund I, Fund II, Alpha Fund and Ultra Fund. Messrs. Kahan are the co-managers of, and each may be deemed to indirectly beneficially own securities beneficially owned by, each of North Peak Management and North Peak GP. Each Reporting Person disclaims beneficial ownership of the shares of Common Stock held directly by the other Reporting Persons. Each Reporting Person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement. Each Reporting Person may be deemed to be a member of a group with respect to the Issuer or securities of the Issuer for the purposes of Section 13(d) or 13(g) of the Act. Each of the Reporting Persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such Reporting Person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the Issuer or otherwise with respect to the Issuer or any securities of the Issuer or (ii) a member of any group with respect to the Issuer or any securities of the Issuer. The address of the principal business office of each of the Reporting Persons is c/o North Peak Capital Management, LLC, 405 Lexington Avenue, Suite 5001, New York, NY 10174. See Item 4 on the cover page(s) hereto. Y See Item 9 on the cover page(s) hereto. See Item 11 on the cover page(s) hereto. See Item 5 on the cover page(s) hereto. See Item 6 on the cover page(s) hereto. See Item 7 on the cover page(s) hereto. See Item 8 on the cover page(s) hereto. Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit 99.1 Joint Filing Agreement (filed herewith) North Peak Capital Management, LLC /s/ Jeremy Kahan 03/03/2026 North Peak Capital GP, LLC /s/ Jeremy Kahan 03/03/2026 North Peak Capital Partners, LP /s/ Jeremy Kahan 03/03/2026 North Peak Capital Partners II, LP /s/ Jeremy Kahan 03/03/2026 North Peak Capital Alpha Fund, LP /s/ Jeremy Kahan 03/03/2026 North Peak Capital Ultra Fund, LP /s/ Jeremy Kahan 03/03/2026 Michael Kevin Kahan /s/ Michael Kahan 03/03/2026 Jeremy Steven Kahan /s/ Jeremy Kahan 03/03/2026